Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to learn about the safety of the study medicine called PF-08049820 in healthy adults. The study will also see:
The study medicine is developed for the treatment of moderate to severe atopic dermatitis, also known as eczema. People with this condition may have severe itching and rashes on the skin.
The study is seeking participants who:
Are males or females who can no longer have children.
Are 18 to 65 years old.
Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds).
For group 3 only:
Have 4 biological Japanese grandparents who were born in Japan.
The study has 3 groups. In groups 1 and 2, there may be up to four dosing periods. During each dosing period, participants will take a single dose of the study medicine or placebo as liquid by mouth with or without food at the study clinic. A placebo does not have any medicine in it but looks just like the medicine being studied.
The participants will stay at the study clinic for about 8 days and then can go home. During this time, the study team will observe the participants and take some urine and blood samples to test the level of the study medicine.
The participants will return to the study clinic up to three more times to complete up to four dosing periods separated by at least 2 weeks.
The participants will take increasing amounts of study medicine during each dosing period. After completion of the final dosing period, the participants will receive a follow-up telephone call about a month later.
Group 3 may or may not be needed and will be decided by the study team if needed to collect results from participants who have 4 biological Japanese grandparents who were born in Japan. If group 3 is needed, then there will only be one dosing period as described above.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
Healthy males and females who can no longer have children.
Body mass index (BMI) of 16-32 kg/m2; and a total body weight >50kg (110 lb.). Japanese participants only: a total body weight >45 kg is acceptable.
Cohort 3 only:
Have 4 biological Japanese grandparents who were born in Japan
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
21 participants in 3 patient groups
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal